APTX | Aptinyx Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.0900 - 0.0960
52 Week Range	0.0090 - 0.7200
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	231,126
Average Volume	132,918
Shares Outstanding	N/A
Market Cap	4,130,657
Sector	Healthcare
Industry	Biotechnology
IPO Date	2018-06-21

Valuation
Profitability
Growth
Health
P/E Ratio	-0.10
Forward P/E Ratio	N/A
EPS	-0.98
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	12
Country	USA
Website	APTX

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

APTX's peers: ALRN, ABVC

*Chart delayed

Analyzing fundamentals for APTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see APTX Fundamentals page.

Watching at APTX technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on APTX Technicals page.